º»¹® ¹Ù·Î°¡±â

·Î±×ÀÎ ¹Ù·Î°¡±â


¾Ëº¸Á¨ÄÚ¸®¾Æ(ÁÖ) ±â¾÷Á¤º¸

¾Ëº¸Á¨ÄÚ¸®¾Æ(ÁÖ)

°ü½É±â¾÷ Ãß°¡Çϰí ä¿ë¼Ò½Ä ¹Þ±â

  • »ç¾÷³»¿ë : ¾ç¾à Á¦Á¶¾÷
  • ´ëÇ¥ÀÚÀ念Èñ
  • ¼³¸³ÀÏ1958³â 1¿ù 7ÀÏ
  • ¸ÅÃâ¾× 2,710¾ï 849¸¸¿ø (2025)
  • »ç¿ø¼ö 445 ¸í ÀçÁ÷Áß
  • Æò±Õ¿¬ºÀ5,537¸¸¿ø
  • ÀÚº»±Ý 501¾ï 904¸¸¿ø

ȸ»ç¼Ò°³

ȸ»ç¼Ò°³

Alvogen is a multinational, privately owned pharmaceuticals company focused on developing, manufacturing and distributing generic, brand, over-the-counter brands (OTC) and biosimilar products. With more than 200 pharmaceutical projects in development and registration, the group¡¯s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of: oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has commercial operations in over 30 countries with 2,000 employees. North America is Alvogen¡¯s single largest market and other key markets include: South-Korea, Romania, Bulgaria, Hungary, Taiwan, Russia and China.

À繫ÇöȲ

ÀÚº»ÃѰè¸ÅÃâ¾×¼øÀÌÀͰá»êÀÏ
2,087¾ï 5,770¸¸¿ø 2,710¾ï 849¸¸¿ø 183¾ï 5,658¸¸¿ø2025.12.31

´ÜÀ§: ¹é¸¸¿ø

°á»ê ³âµµÀÚº»ÃѰè¸ÅÃâ¾×¼øÀÌÀÍ
2025 2,087¾ï 5,770¸¸¿ø ¡è 2,710¾ï 849¸¸¿ø ¡è 183¾ï 5,658¸¸¿ø ¡è
2024 1,885¾ï 9,649¸¸¿ø ¡è 2,480¾ï 2,129¸¸¿ø ¡è 153¾ï 8,867¸¸¿ø ¡é
2023 1,764¾ï 8,069¸¸¿ø 2,377¾ï 8,044¸¸¿ø 210¾ï 708¸¸¿ø

Á¤º¸Á¦°ø: ³ªÀ̽ºµð¿£ºñ

º¹¸®ÈÄ»ý

  • ÈÞ¹«/±â³äÀÏÁÖ5Àϱٹ«,¿¬Â÷,¿ùÂ÷,º¸°ÇÈÞ°¡,°æÁ¶ÈÞ°¡,⸳ÀÏÈÞ¹«
  • 4´ëº¸Çè±¹¹Î¿¬±Ý,ÀǷẸÇè,»êÀ纸Çè,°í¿ëº¸Çè
  • ±³À°/¿©°¡Áö¿øÀÚ±â°è¹ßÁö¿ø,»ç³»µ¿È£È¸
  • º¸Àå/º¸»óÀμ¾Æ¼ºê,¿ì¼ö»ç¿øÆ÷»ó,Àå±â±Ù¼ÓÆ÷»ó,ÅðÁ÷±Ý,ÅðÁ÷¿¬±Ý
  • ±Ù¹«È¯°æ/ÆíÀǽĴë,±³Åëºñ,ÁÖÅÃÀÚ±Ý,ÃʵîÇÐÀÚ±ÝÁö¿ø,ÁßµîÇÐÀÚ±ÝÁö¿ø,°íµîÇÐÀÚ±ÝÁö¿ø,´ëÇÐÇÐÀÚ±ÝÁö¿ø

±â¾÷À§Ä¡

  • ÁÖ¼Ò : ¼­¿ïƯº°½Ã ¿µµîÆ÷±¸ ±¹Á¦±ÝÀ¶·Î 10 13Ãþ (¿©Àǵµµ¿,¼­¿ï±¹Á¦±ÝÀ¶¼¾ÅÍ)
  • ȨÆäÀÌÁö : http://www.alvogenkorea.com
  • ¿©Àǵµ¿ª 5¹øÃⱸ µµº¸ 10ºÐÀ̳»

µ¿ÀÏ ±â¾÷ÀÌ¶óµµ Å¸Áö¿ª ä¿ëÀÇ °æ¿ì, ȸ»ç ÁÖ¼Ò¿Í Àα٠ÁöÇÏö Á¤º¸°¡ »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.